July 2016 Newsletter

I’m writing to you as a person with diabetes or a loved one who I know is concerned with making sure that new diabetes technology is approved, covered and utilized to their fullest capacity by the most people.

Back to School Advocacy Webinar for Parents of Children with Diabetes You will hear from parents and advocates who have been there - on behalf of their own children and through their work with other parents who want to keep their children safe at school!

View the results of last month's survey and VOTE a new July survey!

An invaluable source for people with diabetes as well as the diabetes experts who care for them. Use of real-time continuous glucose monitors among people with type 1 and type 2 diabetes is growing rapidly and should continue to grow until an artificial pancreas is brought to market.

A company called Senseonics has announced that its Eversense Continuous Glucose Monitor (CGM) received CE Mark approval in Europe. It will launch is Sweden in June and in Norway and Denmark by the end of the year.

When new drugs hit the market, lots of research has been done to evaluate their safety and effectiveness. When you hear about drugs that are in development and the results of research that is being done, you are often hearing about phase III clinical trial results.

The Leona M. and Harry B. Helmsley Charitable Trust has a Type 1 Diabetes Program, and in May they announced $1.4 million in grants to support the study of unusual clinical cases of Type 1 Diabetes (T1D).

Some encouraging research was presented at the European Congress of Endocrinology meeting in May of this year. It showed that improving the A1c seems to ease loss of bone mineral density (BMD)and bone turnover in people with type 1 diabetes.

The results of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial of the glucose-lowering drug liraglutide